ATNM ACTINIUM PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ACTINIUM PHARMACEUTICALS INC reported revenue of $35.0M, net income of $27.9M and diluted EPS of $0.89; for the fiscal year ended December 2025 revenue was $90.0K.

ATNM annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $90.0K, gross profit n/a, operating income −$36.2M, net income −$33.9M (margin -37652.2%), EPS −$1.09
• Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$42.1M, net income −$38.2M (margin n/a), EPS −$1.27
• Fiscal year ended Dec 2023: revenue $81.0K, gross profit n/a, operating income −$51.9M, net income −$48.8M (margin -60269.1%), EPS −$1.83
• Fiscal year ended Dec 2022: revenue $1.03M, gross profit n/a, operating income −$34.1M, net income −$33.0M (margin -3205.5%), EPS −$1.37
• Fiscal year ended Dec 2021: revenue $1.14M, gross profit n/a, operating income −$25.0M, net income −$24.8M (margin -2165.6%), EPS −$1.20

ATNM quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $35.0M, net income $27.9M, EPS $0.89
• Quarter ended Mar 31, 2026: revenue n/a, net income −$5.52M, EPS −$0.18
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$5.94M, EPS −$0.20
• Quarter ended Sep 30, 2025: revenue $90.0K, net income −$5.13M, EPS −$0.16
• Quarter ended Jun 30, 2025: revenue n/a, net income −$6.88M, EPS −$0.22
• Quarter ended Mar 31, 2025: revenue n/a, net income −$15.9M, EPS −$0.51
• Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$6.65M, EPS −$0.21
• Quarter ended Sep 30, 2024: revenue n/a, net income −$11.6M, EPS −$0.37
• Quarter ended Jun 30, 2024: revenue n/a, net income −$11.4M, EPS −$0.38
• Quarter ended Mar 31, 2024: revenue n/a, net income −$8.67M, EPS −$0.31
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$9.32M, EPS −$0.33
• Quarter ended Sep 30, 2023: revenue n/a, net income −$13.3M, EPS −$0.49
• Quarter ended Jun 30, 2023: revenue n/a, net income −$15.2M, EPS −$0.58
• Quarter ended Mar 31, 2023: revenue n/a, net income −$11.0M, EPS −$0.43
• Quarter ended Dec 31, 2022 (from the annual report): revenue $0 (down 100.0% year over year), net income −$10.6M, EPS −$0.43
• Quarter ended Sep 30, 2022: revenue $45.0K (down 80.7% year over year), net income −$9.47M, EPS −$0.38
• Quarter ended Jun 30, 2022: revenue $45.0K (down 83.1% year over year), net income −$7.77M, EPS −$0.33
• Quarter ended Mar 31, 2022: revenue $940K (up 51.1% year over year), net income −$5.13M, EPS −$0.23
• Quarter ended Dec 31, 2021 (from the annual report): revenue $23.0K, net income −$8.01M, EPS −$0.36
• Quarter ended Sep 30, 2021: revenue $233K, net income −$6.42M, EPS −$0.30

ATNM cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$24.6M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$33.1M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$47.3M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $8.64M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$20.9M, share buybacks n/a

ATNM balance sheet

• Jun 30, 2026: cash $36.5M, total assets $40.2M, total liabilities $9.86M, shareholders' equity $30.3M
• Mar 31, 2026: cash $42.1M, total assets $45.4M, total liabilities $43.1M, shareholders' equity $2.30M
• Dec 31, 2025: cash $48.0M, total assets $51.8M, total liabilities $43.9M, shareholders' equity $7.83M
• Sep 30, 2025: cash $53.4M, total assets $56.2M, total liabilities $42.4M, shareholders' equity $13.8M
• Jun 30, 2025: cash $59.9M, total assets $63.0M, total liabilities $44.0M, shareholders' equity $19.0M
• Mar 31, 2025: cash $65.3M, total assets $68.6M, total liabilities $43.0M, shareholders' equity $25.7M
• Dec 31, 2024: cash $72.9M, total assets $76.9M, total liabilities $44.1M, shareholders' equity $32.8M
• Sep 30, 2024: cash $78.7M, total assets $82.1M, total liabilities $43.9M, shareholders' equity $38.2M

What is ATNM's revenue?

ACTINIUM PHARMACEUTICALS INC reported $90.0K of revenue for the fiscal year ended December 2025.

Is ATNM profitable?

Yes. ACTINIUM PHARMACEUTICALS INC earned $11.3M over the last four quarters.

What is ATNM's EPS?

Diluted earnings per share over the last four quarters were $0.35; $0.89 in the latest quarter.

ATNM ownership and insider trades · All stocks